Advice
following a full submission:
dabigatran etexilate (Pradaxa®) is accepted for use within NHS Scotland.
Indication under review: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Dabigatran etexilate was non-inferior to a vitamin K antagonist for recurrent symptomatic venous thromboembolism events (VTE) and death related to VTE in three phase III studies (two in the treatment of DVT/PE and one in the prevention of recurrent DVT/PE).
The economic case was based on evidence relating to a maximum of 18 months treatment so the cost-effectiveness of longer term use is uncertain.
Download detailed advice199KB (PDF)
Medicine details
- Medicine name:
- dabigatran etexilate (Pradaxa)
- SMC ID:
- 995/14
- Indication:
- For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 October 2014